News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
511,682 Results
Type
Article (48310)
Company Profile (37)
Press Release (463335)
Multimedia
Podcasts (35)
Webinars (12)
Section
Business (139614)
Career Advice (1179)
Deals (26408)
Drug Delivery (92)
Drug Development (63828)
Employer Resources (93)
FDA (13021)
Job Trends (11351)
News (247897)
Policy (25722)
Tag
2027 Biotech Bay Standard (1)
Academia (2732)
Academic (1)
Accelerated approval (32)
Adcomms (18)
Allergies (117)
Alliances (34139)
ALS (128)
Alzheimer's disease (1408)
Antibody-drug conjugate (ADC) (229)
Approvals (13319)
Artificial intelligence (360)
Autoimmune disease (113)
Automation (20)
Bankruptcy (276)
Best Places to Work (9072)
BIOSECURE Act (17)
Biosimilars (154)
Biotechnology (31)
Bladder cancer (138)
Brain cancer (53)
Breast cancer (513)
Cancer (3936)
Cardiovascular disease (307)
Career advice (976)
Career pathing (17)
CAR-T (234)
CDC (40)
Celiac Disease (1)
Cell therapy (574)
Cervical cancer (34)
Clinical research (54862)
Collaboration (1249)
Company closure (1)
Compensation (357)
Complete response letters (57)
COVID-19 (2464)
CRISPR (60)
C-suite (727)
Cystic fibrosis (110)
Data (5278)
Decentralized trials (1)
Denatured (14)
Depression (113)
Diabetes (386)
Diagnostics (5290)
Digital health (26)
Diversity (8)
Diversity, equity & inclusion (30)
Drug discovery (169)
Drug pricing (128)
Drug shortages (18)
Duchenne muscular dystrophy (192)
Earnings (55856)
Editorial (36)
Employer branding (11)
Employer resources (84)
Events (62831)
Executive appointments (843)
FDA (15710)
Fibrodysplasia Ossificans Progressiva (4)
Friedreich's ataxia (7)
Frontotemporal dementia (18)
Funding (997)
Gene editing (137)
Generative AI (22)
Gene therapy (418)
GLP-1 (674)
Government (3677)
Grass and pollen (4)
Guidances (367)
Healthcare (14773)
HIV (47)
Huntington's disease (31)
IgA nephropathy (71)
Immunology and inflammation (162)
Immuno-oncology (40)
Indications (97)
Infectious disease (2674)
Inflammatory bowel disease (157)
Inflation Reduction Act (10)
Influenza (97)
Intellectual property (236)
Interviews (190)
IPO (13382)
IRA (32)
Job creations (2550)
Job search strategy (841)
JPM (24)
Kidney cancer (16)
Labor market (54)
Layoffs (411)
Leadership (15)
Legal (6414)
Liver cancer (69)
Longevity (7)
Lung cancer (541)
Lymphoma (335)
Machine learning (29)
Management (25)
Manufacturing (607)
MASH (140)
Medical device (10340)
Medtech (10376)
Mergers & acquisitions (13969)
Metabolic disorders (918)
Multiple sclerosis (149)
NASH (14)
Neurodegenerative disease (239)
Neuropsychiatric disorders (57)
Neuroscience (2398)
Neurotech (1)
NextGen: Class of 2026 (4900)
Non-profit (3578)
Now hiring (32)
Obesity (369)
Opinion (117)
Ovarian cancer (149)
Pain (165)
Pancreatic cancer (196)
Parkinson's disease (223)
Partnered (26)
Patents (460)
Patient recruitment (408)
Peanut (47)
People (46372)
Pharmaceutical (13)
Pharmacy benefit managers (23)
Phase 1 (16415)
Phase 2 (24181)
Phase 3 (18795)
Pipeline (4664)
Policy (194)
Postmarket research (1932)
Preclinical (6927)
Press Release (42)
Prostate cancer (198)
Psychedelics (33)
Radiopharmaceuticals (228)
Rare diseases (626)
Real estate (4520)
Recruiting (38)
Regulatory (19348)
Reports (33)
Research institute (2065)
Resumes & cover letters (195)
Rett syndrome (24)
RNA editing (6)
RSV (60)
Schizophrenia (131)
Series A (143)
Series B (105)
Service/supplier (5)
Sickle cell disease (73)
Special edition (12)
Spinal muscular atrophy (125)
Sponsored (31)
Startups (2400)
State (2)
Stomach cancer (10)
Supply chain (70)
Tariffs (44)
The Weekly (21)
Vaccines (872)
Venture capital (43)
Weight loss (231)
Women's health (69)
Worklife (5)
Date
Today (96)
Last 7 days (404)
Last 30 days (1641)
Last 365 days (22566)
2026 (2728)
2025 (22909)
2024 (27201)
2023 (30936)
2022 (38205)
2021 (44302)
2020 (43061)
2019 (34678)
2018 (26726)
2017 (24699)
2016 (22748)
2015 (27251)
2014 (19907)
2013 (16779)
2012 (17888)
2011 (18530)
2010 (16771)
Location
Africa (540)
Alabama (76)
Alaska (5)
Arizona (188)
Arkansas (11)
Asia (30962)
Australia (5304)
California (8323)
Canada (2732)
China (874)
Colorado (375)
Connecticut (388)
Delaware (233)
Europe (66102)
Florida (1408)
Georgia (272)
Hawaii (2)
Idaho (42)
Illinois (672)
India (45)
Indiana (428)
Iowa (18)
Japan (339)
Kansas (110)
Kentucky (30)
Louisiana (22)
Maine (59)
Maryland (1009)
Massachusetts (5451)
Michigan (247)
Minnesota (406)
Mississippi (6)
Missouri (107)
Montana (30)
Nebraska (16)
Nevada (110)
New Hampshire (68)
New Jersey (2554)
New Mexico (16)
New York (2472)
North Carolina (1095)
North Dakota (4)
Northern California (4018)
Ohio (235)
Oklahoma (18)
Oregon (23)
Pennsylvania (1781)
Puerto Rico (21)
Rhode Island (35)
South America (799)
South Carolina (60)
South Dakota (1)
Southern California (3342)
Tennessee (148)
Texas (1472)
United States (30267)
Utah (253)
Virginia (218)
Washington D.C. (57)
Washington State (728)
West Virginia (4)
Wisconsin (72)
Wyoming (2)
511,682 Results for "mississippi state university".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pharm Country
Halberd and Mississippi State University to Commence Stage II Advanced TBI Nasal Spray Testing
Halberd Corporation’s Traumatic Brain Injury mitigating nasal spray testing protocols at Mississippi State University were approved by the Institutional Animal Care and Use Committee.
February 8, 2024
·
3 min read
Pharm Country
Halberd Corporation Plans to Extend Research Partnership with Mississippi State University
Halberd Corporation is in talks with Mississippi State University to extend its original six-month research arrangement by an additional two years, encompassing yet-to-be defined projects.
November 15, 2023
·
3 min read
Pharm Country
Halberd-Mississippi State University (MSU) Testing of TBI Nasal Spray Progresses
Halberd Corporation’s Traumatic Brain Injury mitigation research on Halberd’s patent-pending nasal spray continues at Mississippi State University.
August 14, 2023
·
4 min read
Business
Halberd’s Traumatic Brain Injury (TBI) Testing Results Replicated at Mississippi State University (MSU)
Halberd Corporation’s (OTC PINK:HALB) proprietary nasal spray testing results to mitigate the effects of Traumatic Brain Injury (TBI) at Mississippi State University (MSU) replicated the earlier dramatic results.
October 4, 2023
·
4 min read
Press Releases
60 Degrees Pharmaceuticals Exercises License Option with Florida State University for Large-Scale Purification of Castanospermine for Non-Rx Use
January 29, 2026
·
5 min read
Pharm Country
Halberd’s Successful Completion of Sampling Phase Marks Major Milestone for Project at Mississippi State University (MSU)
Halberd Corporation (OTC PINK:HALB) announced Mississippi State University (MSU) has finalized the collection of tissue samples from a quantity of the planned test subjects.
August 22, 2023
·
3 min read
Policy
Astounding Early Test Results of Halberd’s Traumatic Brain Injury (TBI) Project at Mississippi State University (MSU)
Halberd Corporation’s research at Mississippi State University has shown significant reduction in two key markers of traumatic brain injury in early testing of Halberd’s patent-pending nasal spray to mitigate the effects of TBI.
September 6, 2023
·
4 min read
Drug Development
Halberd Initial Preclinical Testing Phase at Mississippi State University (MSU) Complete
Halberd Corporation announced Mississippi State University has completed the initial phase of its preclinical model to establish baseline testing parameters and study endpoints for Halberd’s groundbreaking patent-pending nasal spray.
May 23, 2023
·
4 min read
Drug Development
Halberd Begins Preclinical Testing at Mississippi State University (MSU)
Halberd Corporation (OTC PINK:HALB) has announced that preclinical testing is now underway at Mississippi State University (MSU) for its groundbreaking patent-pending nasal spray designed to suppress the negative effects of Traumatic Brain Injury (TBI).
April 11, 2023
·
3 min read
Press Releases
Lupin Launches Dasatinib Tablets in the United States
February 2, 2026
·
2 min read
1 of 51,169
Next
